Baxter International appears to have put its flu vaccine development program back on track. Researchers report that an early-stage trial of its seasonal flu therapy demonstrates "strong antibody responses and good tolerability." Report [1]
Links:
[1] http://www.chicagotribune.com/business/chi-tue_baxter0724jul24,0,5182031.story